{"id":"NCT00312845","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","officialTitle":"A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2010-06","completion":"2010-07","firstPosted":"2006-04-11","resultsPosted":"2011-07-26","lastUpdate":"2012-06-25"},"enrollment":676,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin's Lymphoma"],"interventions":[{"type":"DRUG","name":"Bortezomib + Rituximab","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]}],"arms":[{"label":"Bortezomib + Rituximab","type":"EXPERIMENTAL"},{"label":"Rituximab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.","effectByArm":[{"arm":"Bortezomib + Rituximab","deltaMin":389,"sd":null},{"arm":"Rituximab","deltaMin":334,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.039"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":10},"locations":{"siteCount":206,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Cyprus","Czechia","Finland","France","Germany","Greece","Hungary","India","Israel","Italy","Mexico","New Zealand","Poland","Portugal","Puerto Rico","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["23088650","21724462"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":334},"commonTop":["Fatigue","Cough","Headache","Back pain","Pain in extremity"]}}